Private French drugmaker Ipsen said on Thursday it had acquired a small British biotechnology firm prior to a possible initial public offering, in the latest sign of a pick-up in activity in the European sector.
Private French drugmaker Ipsen said on Thursday it had acquired a small British biotechnology firm prior to a possible initial public offering, in the latest sign of a pick-up in activity in the European sector.
